Evommune
EVMN

Evommune (EVMN) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
NeedhamInitiated CoverageBuy$28.00Aug 26, 2026
RBC CapitalMaintainedOutperform$29.00 from $30.00Aug 7, 2026
HC Wainwright & Co.MaintainedNeutralAug 3, 2026
HC Wainwright & Co.DowngradedBuy → NeutralJun 30, 2026
Morgan StanleyMaintainedOverweight$26.00 from $55.00Jun 30, 2026
William BlairDowngradedOutperform → Market PerformJun 29, 2026
HC Wainwright & Co.MaintainedBuy$50.00May 26, 2026
Morgan StanleyMaintainedOverweight$55.00 from $54.00May 11, 2026
RBC CapitalMaintainedOutperform$48.00Apr 10, 2026
HC Wainwright & Co.MaintainedBuy$50.00 from $65.00Mar 18, 2026
Clear StreetInitiated CoverageBuy$53.00Mar 18, 2026
HC Wainwright & Co.MaintainedBuy$65.00 from $35.00Feb 10, 2026
OppenheimerInitiated CoverageOutperform$42.00Jan 22, 2026
Raymond JamesInitiated CoverageStrong Buy$40.00Jan 8, 2026
HC Wainwright & Co.Initiated CoverageBuy$35.00Jan 6, 2026
Leerink PartnersInitiated CoverageOutperform$42.00Dec 1, 2025
Cantor FitzgeraldInitiated CoverageOverweightDec 1, 2025
Evercore ISI GroupInitiated CoverageOutperform$40.00Dec 1, 2025
William BlairInitiated CoverageOutperformDec 1, 2025
Morgan StanleyInitiated CoverageOverweight$36.00Dec 1, 2025

Frequently asked questions

  • What is the latest analyst rating on EVMN?

    On Aug 26, 2026, Needham initiated coverage of Evommune at Buy with a price target of $28.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.